AstraZeneca shrugs off pharma’s emerging markets slowdown, but Lilly’s suffering

Carly Helfand

After Q2's glacial growth, industry watchers wondered just how slow pharma could go in developing countries. As it turns out, they found a way to decelerate in Q3.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS